They may recommend close monitoring of your weight and overall health
Pancreatitis (rare): GLP-1 medications have a very small risk of pancreatitis (inflammation of the pancreas)
The animals were administered a fixed daily dose of 0.2 mg/kg of semaglutide in 0.5 mL (Ozempic, Novo Nordisk, Bagsvrd, Denmark) subcutaneously on the back
Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH programme)
Distribute this across three meals, targeting 30-40 grams at each meal
Clinical Study Disclaimer: *Based on Ivims published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks